Laidlaw Initiates Coverage on Senti Bio with Buy Rating and $5 Target Price

Laidlaw initiates coverage on Senti Bio (SNTI) with a Buy rating and a $5 price target. The biotech company is focused on innovative CAR-NK therapies, with its lead therapy, SENTI-202, showing promising results in Phase I trials for high-risk relapsed or refractory acute myeloid leukemia. Analysts forecast an average one-year price target of $12.00, implying a 237.08% upside from the current price of $3.56.

Laidlaw Financial Research has initiated coverage on Senti Bio (SNTI) with a Buy rating and a $5 price target. The biotech company specializes in innovative CAR-NK (Chimeric Antigen Receptor Natural Killer) therapies, with its lead therapy, SENTI-202, demonstrating promising results in Phase I trials for high-risk relapsed or refractory acute myeloid leukemia (AML).

SENTI-202, an allogeneic, logic-gated selective CD33/FLT3 CAR-NK, achieved an objective response rate (ORR) of 71.4% in 7 evaluable patients with R/R AML, according to updated Phase I results presented at the AACR’25 meeting. No dose-limiting toxicities (DLTs) were observed, highlighting the potential of this therapy in AML treatment.

Analysts forecast an average one-year price target of $12.00, implying a 237.08% upside from the current price of $3.56. The rating and price target reflect the company's promising pipeline and the potential of its lead therapy in addressing an unmet medical need in AML treatment.

References:
[1] https://www.linkedin.com/pulse/cgt-watch-newsletter-may25-edition-oncofocus-solutions-m5yac